CareLit Fachartikel

Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study

K Deterding, C Spinner, E Schott, T Welzel, G Gerken, H Klinker, U Spengler, J Wiegand, J Schulze zur Wiesch, A Pathil, M Cornberg, A Umgelter, C Zöllner, S Zeuzem, H von der Leyen, D von Witzendorff, MP Manns, H Wedemeyer · Zeitschrift für Gastroenterologie · 2016 · Heft 08

Dokument
1146138
CareLit-ID
Jahr
2016
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Zeitschrift für Gastroenterologie
Autor:innen
K Deterding, C Spinner, E Schott, T Welzel, G Gerken, H Klinker, U Spengler, J Wiegand, J Schulze zur Wiesch, A Pathil, M Cornberg, A Umgelter, C Zöllner, S Zeuzem, H von der Leyen, D von Witzendorff, MP Manns, H Wedemeyer
Ausgabe
Heft 08 / 2016
Seiten
–
Erschienen: 2016-08-16 00:00:00
ISSN
0044-2771
DOI
10.1055/s-0036-1587008

Zusammenfassung

Background: Early treatment of acute hepatitis C virus (HCV) infection with interferon alfa monotherapy for 12 – 24 weeks is highly effective but is associated with frequent unfavorable side effects. There is no fully published study yet exploring the safety, efficacy and required treatment duration of interferon-free treatment of acute hepatitis C virus monoinfection. Methods: The German HepNet Acute HCV IV Study was designed as a single arm, prospective multicenter pilot study to evaluate the efficacy and safety of treatment with SOF/LDV for 6 weeks without ribavirin in patients with acute genotype 1 HCV monoi…

Schlagworte

Hepatitis Bilirubin Alanine Zeitschrift für Gastroenterologie